Last reviewed 2026-04-23 · How we verify

RTX infusions

RTX (rituximab) is a chimeric monoclonal antibody that depletes B cells by binding to CD20 antigen on their surface.

RTX (rituximab) is a chimeric monoclonal antibody that depletes B cells by binding to CD20 antigen on their surface. Used for Systemic lupus erythematosus (SLE), Lupus nephritis.

At a glance

Mechanism of action

RTX targets CD20, a surface antigen expressed on B lymphocytes, leading to B cell depletion through antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). This reduces autoimmune-mediated inflammation and is used in conditions driven by pathogenic B cells and autoantibodies.

Approved indications

• Systemic lupus erythematosus (SLE)
• Lupus nephritis

Common side effects

• Infusion reactions
• Infections
• Cytopenias
• Fatigue
• Headache

Key clinical trials

• Recapturing Immune Tolerance to Pegloticase for the Management of Tophaceous Gout (PHASE1)
• High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN) (PHASE3)
• NK010 or NK042 in Combination With Rituximab for Refractory Systemic Lupus Erythematosus/Lupus Nephritis (PHASE1)
• Rituximab (RTX) Therapy in Patients With Active TAO (PHASE4)
• Synergetic B-cell Immunomodulation in SLE - 2nd Study. (PHASE3)
• Rituximab, Cyclophosphamide, and Corticosteroids in Primary Membranous Nephropathy (NA)
• Safety and Efficacy of Intrathecal Rituximab in 16 Children of Stage Ⅲ、ⅣNon-Hodgkin Lymphoma
• A Randomized, Controlled Clinical Study of Rituximab in Treatment of Primary IgA Nephropathy (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.